The Biologics News and Reports Portal

Show Cart

All Products

Results 61 - 80 of 190

May 2018 TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

2,150.00 €

Mar 2018 Competitor Analysis: CDK9 and Mcl-1 Inhibitors

200.00 €

Mar 2018 Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

80.00 €

Jan 2018 Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

2,300.00 €

Nov 2017 Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update

450.00 €

Oct 2017 Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics

3,080.00 €

4,400.00 €

(Discount: 30.00%)

Aug 2017 Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

300.00 €

Jun 2017 mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

2,250.00 €

Apr 2017 Competitor Analysis: Kallikrein Inhibitors 2017

150.00 €

Mar 2017 Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

400.00 €

Mar 2017 Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins

70.00 €

Mar 2017 Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars

200.00 €

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

2,150.00 €

Shopping cart

Cart empty

Latest report

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Featured Products

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Latest Target Pipeline

STING Agonists & Antagonists

Shopping cart

Cart empty

Latest report

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Featured Products

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

All Products

Jun 2018 Competitor Analysis: MAGE-A-Targeted Immunotherapy

Jun 2018 Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

Jun 2018 Competitor Analysis: hTERT-Targeted Immunotherapy

Jun 2018 Competitor Analysis: WT1-Targeted Immunotherapy

Jun 2018 Competitor Analysis: PRAME-Targeted Immunotherapy

May 2018 Report Package: TCR-Based Antibody and T-Cell Immunotherapy

May 2018 Competitor Analysis: Survivin-Targeted Immunotherapy

May 2018 TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Mar 2018 Competitor Analysis: CDK9 and Mcl-1 Inhibitors

Mar 2018 Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Jan 2018 Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Nov 2017 Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update

Oct 2017 Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics

Aug 2017 Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

Jun 2017 mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

Apr 2017 Competitor Analysis: Kallikrein Inhibitors 2017

Mar 2017 Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

Mar 2017 Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins

Mar 2017 Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing